View Older Stories View More Recent Stories

Dec 21, 2022 05:01PM Mirati Therapeutics (MRTX) Granted FDA Breakthrough Therapy Designation for adagrasib with cetuximab
Dec 21, 2022 05:00PM Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib
Dec 13, 2022 04:00PM Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Dec 13, 2022 06:29AM Mirati Therapeutics (MRTX) announces accelerated approval from FDA for KRAZATI to treat NSCLC
Dec 12, 2022 06:42PM Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dec 6, 2022 07:14AM Zai Lab Partner Mirati Therapeutics (MRTX) Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic NSCLC
Dec 5, 2022 06:10PM Zai Lab Partner Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dec 5, 2022 06:05PM Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Dec 2, 2022 08:02AM Mirati Therapeutics (MRTX) phase 3 SAPPHIRE study to continue to final analysis
Dec 2, 2022 08:00AM Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study
Nov 28, 2022 08:00AM Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO
Nov 8, 2022 04:10PM Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
Nov 8, 2022 04:06PM Mirati Therapeutics (MRTX) Appoints Alan Sandler as EVP and Chief Medical Officer
Nov 8, 2022 04:05PM Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team
Nov 7, 2022 08:17AM Incyte (INCY) And Mirati (MRTX) Enters Collaboration and Supply Agreement to Evaluate INCB99280
Nov 7, 2022 08:15AM Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors
Nov 2, 2022 04:15PM Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Oct 25, 2022 04:30PM Mirati Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Updates
Oct 12, 2022 08:00AM Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C
Oct 5, 2022 04:30PM Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Sep 22, 2022 04:30PM Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
Sep 7, 2022 06:05PM Mirati Therapeutics Presents Late-Breaking Adagrasib Monotherapy and Combination Results in Advanced Colorectal Cancer
Sep 2, 2022 06:07PM Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Aug 31, 2022 04:30PM Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
Aug 4, 2022 04:30PM Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Aug 3, 2022 04:01PM Mirati Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
Jul 20, 2022 04:30PM Mirati Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Updates
Jun 6, 2022 08:03AM Mirati Therapeutics (MRTX) Reports New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases
Jun 6, 2022 08:00AM New Late-Breaking Data on Investigational Adagrasib Show Regression of Central Nervous System (CNS) Metastases in Patients with KRASG12C-mutated Non-Small Cell Lung Cancer (NSCLC) with Active, Untreat
May 26, 2022 05:01PM Mirati Therapeutics (MRTX) Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
May 26, 2022 05:00PM Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer
May 25, 2022 04:30PM Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
May 19, 2022 04:30PM Mirati Therapeutics (MRTX) Submits MAA to EMA for Investigational Adagrasib as Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lung Cancer
May 19, 2022 04:30PM Mirati Therapeutics Submits Marketing Authorization Application to the European Medicines Agency for Investigational Adagrasib as a Treatment for Previously-Treated KRASG12C-mutated Non-Small Cell Lun
May 16, 2022 04:30PM Mirati Therapeutics (MRTX) Appoints Laurie Stelzer as CFO
May 16, 2022 04:30PM Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer
May 4, 2022 04:01PM Mirati Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Updates
Apr 27, 2022 04:30PM Mirati Therapeutics to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib
Apr 20, 2022 04:30PM Mirati Therapeutics to Report First Quarter 2022 Financial Results and Recent Corporate Updates
Mar 2, 2022 04:33PM Mirati Therapeutics to Participate in the 42nd Annual Cowen Healthcare Conference
Feb 28, 2022 04:01PM Mirati Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
Feb 15, 2022 04:15PM Mirati Therapeutics (MRTX) Announces FDA Accepts New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated NSCLC
Feb 15, 2022 04:15PM U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics' New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
Feb 14, 2022 07:30AM Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2021 and Recent Corporate Updates on February 28, 2022
Feb 2, 2022 04:30PM Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences
Jan 21, 2022 10:01AM Mirati Therapeutics (MRTX) Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers
Jan 21, 2022 10:00AM Mirati Therapeutics Presents Positive Clinical Data with Investigational Adagrasib in Patients with KRASG12C-Mutated Gastrointestinal Cancers
Jan 4, 2022 04:30PM Mirati Therapeutics to Present at the J.P. Morgan 40th Annual Virtual Healthcare Conference
Nov 23, 2021 04:30PM Mirati Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference
Nov 22, 2021 07:33AM Mirati Therapeutics (MRTX), Verastem Oncology (VSTM) Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant NSCLC
View More Recent Stories View Older Stories